Michael Lubbert

Summary

Affiliation: University Hospital
Country: Germany

Publications

  1. pmc A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy
    Michael Lubbert
    Dept of Medicine, Div Hematology Oncology, University of Freiburg Medical Center, Hugstetter Str 55, D 79106 Freiburg, Germany
    Haematologica 97:393-401. 2012
  2. doi request reprint Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Rese
    Michael Lubbert
    Albert Ludwigs University, Freiburg, Germany
    J Clin Oncol 29:1987-96. 2011
  3. doi request reprint Non-intensive treatment with low-dose 5-aza-2'-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients
    M Lubbert
    Division of Hematology and Oncology, University of Freiburg Medical Center, Freiburg, Germany
    Bone Marrow Transplant 44:585-8. 2009
  4. doi request reprint Advances in the treatment of acute myeloid leukemia: from chromosomal aberrations to biologically targeted therapy
    Michael Lubbert
    Division of Hematology Oncology, Department of Medicine, University of Freiburg Medical Center, Freiburg, Germany
    J Cell Biochem 104:2059-70. 2008
  5. doi request reprint Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting
    M Lubbert
    Division Hematology and Oncology, University of Freiburg Medical Center, Freiburg, Germany
    Bone Marrow Transplant 45:627-32. 2010
  6. ncbi request reprint Inhibitors of DNA methylation and histone deacetylation independently relieve AML1/ETO-mediated lysozyme repression
    Rainer Claus
    Division Hematology Oncology, University of Freiburg Medical Center, Hugstetter Str 55, Freiburg D 79106, Germany
    J Leukoc Biol 80:1462-72. 2006
  7. ncbi request reprint The AML1/ETO target gene LAT2 interferes with differentiation of normal hematopoietic precursor cells
    Aitomi Essig
    Department of Hematology and Oncology, University of Freiburg, Medical Center, Freiburg, Germany Electronic address
    Leuk Res 38:340-5. 2014
  8. ncbi request reprint In vivo effects of decitabine in myelodysplasia and acute myeloid leukemia: review of cytogenetic and molecular studies
    Björn Hackanson
    Department of Hematology Oncology, University of Freiburg Medical Center, Freiburg, Germany
    Ann Hematol 84:32-8. 2005
  9. pmc Epigenetic priming of AML blasts for all-trans retinoic acid-induced differentiation by the HDAC class-I selective inhibitor entinostat
    Nadja Blagitko-Dorfs
    Department of Hematology and Oncology, University Medical Center Freiburg, Freiburg, Germany
    PLoS ONE 8:e75258. 2013
  10. ncbi request reprint Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment
    Michael Daskalakis
    Department of Hematology, University of Freiburg Medical Center, Freiburg, Germany
    Blood 100:2957-64. 2002

Detail Information

Publications54

  1. pmc A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy
    Michael Lubbert
    Dept of Medicine, Div Hematology Oncology, University of Freiburg Medical Center, Hugstetter Str 55, D 79106 Freiburg, Germany
    Haematologica 97:393-401. 2012
    ....
  2. doi request reprint Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Rese
    Michael Lubbert
    Albert Ludwigs University, Freiburg, Germany
    J Clin Oncol 29:1987-96. 2011
    ..To compare low-dose decitabine to best supportive care (BSC) in higher-risk patients with myelodysplastic syndrome (MDS) age 60 years or older and ineligible for intensive chemotherapy...
  3. doi request reprint Non-intensive treatment with low-dose 5-aza-2'-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients
    M Lubbert
    Division of Hematology and Oncology, University of Freiburg Medical Center, Freiburg, Germany
    Bone Marrow Transplant 44:585-8. 2009
    ....
  4. doi request reprint Advances in the treatment of acute myeloid leukemia: from chromosomal aberrations to biologically targeted therapy
    Michael Lubbert
    Division of Hematology Oncology, Department of Medicine, University of Freiburg Medical Center, Freiburg, Germany
    J Cell Biochem 104:2059-70. 2008
    ..The use of a variety of molecular biology techniques have identified a large number of genomic abnormalities; the challenge of the next several decades is to identify specific therapies for these molecular defects...
  5. doi request reprint Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting
    M Lubbert
    Division Hematology and Oncology, University of Freiburg Medical Center, Freiburg, Germany
    Bone Marrow Transplant 45:627-32. 2010
    ..Objective responses, including continuous complete donor chimerism, occurred also in patients with poor-risk cytogenetics...
  6. ncbi request reprint Inhibitors of DNA methylation and histone deacetylation independently relieve AML1/ETO-mediated lysozyme repression
    Rainer Claus
    Division Hematology Oncology, University of Freiburg Medical Center, Hugstetter Str 55, Freiburg D 79106, Germany
    J Leukoc Biol 80:1462-72. 2006
    ..Interestingly, inhibitors of DNMTs and HDACs independently relieve repression of this CpG-poor gene in AML1/ETO-positive cells...
  7. ncbi request reprint The AML1/ETO target gene LAT2 interferes with differentiation of normal hematopoietic precursor cells
    Aitomi Essig
    Department of Hematology and Oncology, University of Freiburg, Medical Center, Freiburg, Germany Electronic address
    Leuk Res 38:340-5. 2014
    ..It is tempting to speculate that by affecting the differentiation capacity of normal hematopoietic progenitors, LAT2 may contribute to the pathogenesis of AML. ..
  8. ncbi request reprint In vivo effects of decitabine in myelodysplasia and acute myeloid leukemia: review of cytogenetic and molecular studies
    Björn Hackanson
    Department of Hematology Oncology, University of Freiburg Medical Center, Freiburg, Germany
    Ann Hematol 84:32-8. 2005
    ..Other, thus far unidentified hypermethylated genes may also be targets for demethylating agents...
  9. pmc Epigenetic priming of AML blasts for all-trans retinoic acid-induced differentiation by the HDAC class-I selective inhibitor entinostat
    Nadja Blagitko-Dorfs
    Department of Hematology and Oncology, University Medical Center Freiburg, Freiburg, Germany
    PLoS ONE 8:e75258. 2013
    ..Further investigation of this treatment combination in non-M3 AML patients is therefore warranted, independently of RARβ2 gene silencing by DNA methylation. ..
  10. ncbi request reprint Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment
    Michael Daskalakis
    Department of Hematology, University of Freiburg Medical Center, Freiburg, Germany
    Blood 100:2957-64. 2002
    ....
  11. doi request reprint Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system
    Julie Schanz
    Department of Hematology and Oncology, Georg August University, Robert Koch Str 40, 37075 Goettingen, Germany
    J Clin Oncol 29:1963-70. 2011
    ..Here we investigate the prognostic impact of cytogenetic subgroups compared with that of bone marrow blast count in a large, multicentric, international patient cohort...
  12. doi request reprint HDAC6 as a target for antileukemic drugs in acute myeloid leukemia
    Björn Hackanson
    Department of Hematology Oncology, University of Freiburg Medical Center, Freiburg, Germany
    Leuk Res 36:1055-62. 2012
    ..Preferential acetylation of α-tubulin implies that ST80 might exert its antileukemic effect not through histone reacetylation but rather through inhibition of HDAC6...
  13. ncbi request reprint Myelodysplastic syndrome in transformation to acute myeloid leukemia presenting with diabetes insipidus: due to pituitary infiltration association with abnormalities of chromosomes 3 and 7
    Claudia I Muller
    Department of Haematology Oncology, University of Freiburg Medical Center, Hugstetter Strasse 55, D 79106 Freiburg, Germany
    Eur J Haematol 69:115-9. 2002
    ..J. Haematol. 2001: 66: 66-69). Our report of an MDS with trilineage dysplasia and these karyotypic changes associated with DI indicates that this new entity may also include preleukemic cases...
  14. ncbi request reprint Superiority of prolonged low-dose azanucleoside administration? Results of 5-aza-2'-deoxycytidine retreatment in high-risk myelodysplasia patients
    Björn Rüter
    Division of Hematology Oncology, Department of Internal Medicine I, Albert Ludwigs University Freiburg, Freiburg, Germany
    Cancer 106:1744-50. 2006
    ..Although at least 2 consolidating courses after best response usually are performed, the response to treatment after disease recurrence has not been systematically studied to date...
  15. doi request reprint Decitabine induces very early in vivo DNA methylation changes in blasts from patients with acute myeloid leukemia
    Rainer Claus
    Division Epigenomics and Cancer Risk Factors, German Cancer Research Center, Heidelberg, Germany
    Leuk Res 37:190-6. 2013
    ..In conclusion, complex DAC-induced DNA methylation changes occur very early and imply mechanisms distinct from non-hypomethylating cytosine analogs...
  16. doi request reprint MeDIP coupled with a promoter tiling array as a platform to investigate global DNA methylation patterns in AML cells
    Arzu Yalcin
    Division of Hematology Oncology, Department of Medicine, University Medical Center Freiburg, Germany
    Leuk Res 37:102-11. 2013
    ....
  17. ncbi request reprint Treatment of myelodysplastic syndrome with a DNA methyltransferase inhibitor: lack of evidence for induction of chromosomal instability
    Peter S Haas
    Department of Medicine, Division of Hematology Oncology, University of Freiburg Medical Center, Hugstetter Str 55, D 79106 Freiburg, Germany
    Leuk Res 30:338-42. 2006
    ..8/9 abnormalities were gains or losses of entire chromosomes. The rate and pattern of cytogenetic evolution are thus not higher than in historical MDS cohorts not receiving specific treatment...
  18. ncbi request reprint The DNA demethylating agent 5-aza-2'-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells
    Maika Almstedt
    Department of Medicine, Division Hematology and Oncology, University of Freiburg Medical Center, Freiburg, Germany
    Leuk Res 34:899-905. 2010
    ..The susceptibility of DAC-treated AML cell lines to antigen-specific T-cell recognition has clear implications for future clinical trials combining DAC and specific immunotherapy in AML...
  19. doi request reprint A randomized, open-label, phase I/II trial to investigate the maximum tolerated dose of the Polo-like kinase inhibitor BI 2536 in elderly patients with refractory/relapsed acute myeloid leukaemia
    Carsten Muller-Tidow
    Department of Medicine, Haematology and Oncology, University of Munster, Munster, Germany
    Br J Haematol 163:214-22. 2013
    ..Taken together, Plk inhibition induced cell cycle arrest in AML blasts in vivo and BI 2536 monotherapy showed modest clinical activity in this poor prognosis patient group...
  20. pmc Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome
    Barbara Deschler
    University of Freiburg Medical Center, Freiburg, Germany
    Haematologica 98:208-16. 2013
    ....
  21. ncbi request reprint The silence of the genes: epigenetic disturbances in haematopoietic malignancies
    Björn Hackanson
    University of Freiburg Medical Center, Department of Hematology Oncology, 79106 Freiburg, Germany
    Expert Opin Ther Targets 9:45-61. 2005
    ....
  22. doi request reprint Transcriptional upregulation of p21/WAF/Cip1 in myeloid leukemic blasts expressing AML1-ETO
    Tobias Berg
    Department of Medicine, Division Hematology Oncology, University of Freiburg Medical Center, Hugstetter Str 55, D 79106 Freiburg, Germany
    Haematologica 93:1728-33. 2008
    ..The increased expression of p21/WAF/Cip1 in primary leukemic blasts suggests that elevated p21/WAF/Cip1 levels may contribute to specific features observed in AML1-ETO positive leukemia...
  23. ncbi request reprint DNA hypermethylation of myeloid cells, a novel therapeutic target in MDS and AML
    Claudia I Muller
    University of Freiburg Medical Center, Department Internal Medicine I, Div Hematology Oncology, Albert Ludwigs University, Hugstetter Str, D 79106 Freiburg, Germany
    Curr Pharm Biotechnol 7:315-21. 2006
    ..g. with inhibitors of histone deacetylase activity...
  24. doi request reprint Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: results of a randomized phase III trial by the EORTC and GIMEMA consortium (AML-17)
    Sergio Amadori
    Sergio Amadori and Adriano Venditti, Tor Vergata University Hospital Paolo De Fabritiis, St Eugenio Hospital Roberto Latagliata, University Sapienza Paola Fazi and Marco Vignetti, Gruppo Italiano Malattie Ematologiche dell Adulto, Roma Franca Falzetti, University Hospital, Perugia Domenico Magro, Pugliese Hospital, Catanzaro Giorgina Specchia, University Hospital, Bari, Italy Stefan Suciu and Matthias Karrasch, European Organisation for Research and Treatment of Cancer, Brussels Dominik Selleslag, Algemeen Ziekenhuis St Jan, Brugge Zwi Berneman, University Hospital, Antwerp, Belgium Roberto Stasi, St George s Hospital, London, United Kingdom Helmut R Salih, University Hospital, Tubingen Anthony D Ho, University Hospital, Heidelberg Michael Lübbert, Albert Ludwigs University, Freiburg, Germany Petra Muus and Theo de Witte, Radboud University Medical Centre, Nijmegen Constantijn J M Halkes and Roel Willemze, University Medical Center, Leiden, the Netherlands Xavier Thomas, Edouard Herriot Hospital, Lyon Jean Pierre Marie, St Antoine Hospital, Paris, Germany
    J Clin Oncol 31:4424-30. 2013
    ..This randomized trial evaluated the efficacy and toxicity of sequential gemtuzumab ozogamicin (GO) and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia (AML)...
  25. ncbi request reprint Reversal of p15/INK4b hypermethylation in AML1/ETO-positive and -negative myeloid leukemia cell lines
    Tobias Berg
    Department of Medicine, Division of Hematology Oncology, University of Freiburg Medical Center, Hugstetter Str 55, D 79106 Freiburg, Germany
    Leuk Res 31:497-506. 2007
    ..Further studies of AML1/ETO as a modifier of the epigenotype and sensitivity of myeloid cells to inhibitors of DNMTs and HDACs appear warranted...
  26. ncbi request reprint New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients
    Detlef Haase
    Department of Hematology and Oncology, University of Gottingen, Gottingen, Germany
    Blood 110:4385-95. 2007
    ..Our analyses offer new insights into the prognostic significance of rare chromosomal abnormalities and specific karyotypic combinations in MDS...
  27. doi request reprint Molecular cytogenetic monitoring from CD34+ peripheral blood cells in myelodysplastic syndromes: first results from a prospective multicenter German diagnostic study
    Friederike Braulke
    Department of Hematology and Oncology, University of Goettingen, Germany
    Leuk Res 37:900-6. 2013
    ..We demonstrate that CD34+ PB FISH correlates significantly with CCB analysis and represents a feasible method for a reliable non-invasive cytogenetic monitoring from PB. ..
  28. ncbi request reprint Hematologic and molecular spontaneous remission following sepsis in acute monoblastic leukemia with translocation (9;11): a case report and review of the literature
    Claudia I Muller
    Department of Hematology Oncology, University of Freiburg Medical Center, Hugstetter Str 55, Freiburg, Germany
    Eur J Haematol 73:62-6. 2004
    ..Balanced translocations such as in core binding factor (CBF) leukemias appear somewhat overrepresented. We speculate that AML-specific T cells might be relevant for induction of spontaneous remission and need to be further investigated...
  29. ncbi request reprint Epigenetic targets in hematopoietic malignancies
    Rainer Claus
    Department Internal Medicine I, Division Hematology Oncology, University of Freiburg Medical Center, Hugstetter Str, D 79106 Freiburg, Germany
    Oncogene 22:6489-96. 2003
    ..Studies combining a 're-expressor' strategy with inhibitors of Dnmts and HDACs are underway. Thus, resensitization to biological agents such as retinoids, colony-stimulating factors and other differentiation inducers may be envisioned...
  30. ncbi request reprint Regulation of the adaptor molecule LAT2, an in vivo target gene of AML1/ETO (RUNX1/RUNX1T1), during myeloid differentiation
    Jesús Duque-Afonso
    Department of Haematology Oncology, University of Freiburg, Hugstetter Strasse 55, Freiburg, Germany
    Br J Haematol 153:612-22. 2011
    ....
  31. ncbi request reprint Epigenetic treatment of hematopoietic malignancies: in vivo targets of demethylating agents
    Rainer Claus
    Department Internal Medicine I, Division Hematology Oncology, University of Freiburg Medical Center, Hugstetterstrasse 55, D 79106 Freiburg, Germany
    Semin Oncol 32:511-20. 2005
    ..Thus, demethylating agents and histone deacetylase inhibitors may also induce a T-cell-mediated antileukemic or antitumor effect...
  32. ncbi request reprint The hematopathological basis for studying effects of the demethylating agent 5-aza-2'-deoxycytidine (decitabine) in myelodysplasia
    Hans Eckart Schaefer
    Institute of Pathology, University of Freiburg, Freiburg, Germany
    Ann Hematol 84:67-79. 2005
    ..Emphasis is placed on itemizing the broad spectrum of cytologic and histologic stigmata defining the myelodysplastic categories that are to be considered in this study...
  33. ncbi request reprint Tracing the development of acute myeloid leukemia in CBL syndrome
    Heiko Becker
    Department of Medicine I, Medical Center University of Freiburg, Freiburg, Germany
    Blood 123:1883-6. 2014
    ..The study highlights the development of AML in an adult with CBL syndrome and, more generally, in genetically aberrant but clinically inconspicuous hematopoiesis. ..
  34. ncbi request reprint CD34- hematopoietic stem cells: current concepts and controversies
    Yalin Guo
    Department of Hematology Oncology, University of Freiburg Medical Center, Freiburg, Germany
    Stem Cells 21:15-20. 2003
    ..In this review, current concepts on murine and human CD34(-) HSCs and their relationship with CD34(+) HSCs are discussed...
  35. doi request reprint Epigenetic modification of CCAAT/enhancer binding protein alpha expression in acute myeloid leukemia
    Björn Hackanson
    Department of Molecular Virology, Immunology and Medical Genetics, Division of Human Cancer Genetics, College of Pharmacy, Ohio State University, Columbus, Ohio, USA
    Cancer Res 68:3142-51. 2008
    ..Our results indicate that epigenetic alterations of C/EBP alpha are a frequent event in AML and that epigenetic treatment can result in down-regulation of a key hematopoietic transcription factor...
  36. doi request reprint Occurrence of a germinoma 22 years after resection of a mature cerebral teratoma
    Wibke G Janzarik
    Department of Neurology, Neurocenter, University of Freiburg, Freiburg, Germany
    J Neurooncol 88:217-9. 2008
    ..The correct diagnosis could only be confirmed in a second cerebral biopsy, allowing for proper treatment with radiation therapy. The need to consider metachronous germinoma in this setting is discussed...
  37. ncbi request reprint Side-population cells from different precursor compartments
    Yalin Guo
    University of Freiburg Medical Center, Department of Hematology Oncology, D 79106 Freiburg, Germany
    J Hematother Stem Cell Res 12:71-82. 2003
    ..We conclude that human primitive hematopoietic cells can be isolated via Hoechst staining and that SP cells of various human sources show substantial differences and represent a rare CD34(-) population with stem cell potential...
  38. doi request reprint Clinical results with the DNA hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update
    Tina E Joeckel
    Department of Hematology Oncology, University of Freiburg Medical Center, Freiburg, Germany
    Semin Hematol 49:330-41. 2012
    ....
  39. doi request reprint The role of X-inactivation in the gender bias of patients with acquired alpha-thalassaemia and myelodysplastic syndrome (ATMDS)
    Peter S Haas
    Division of Haematology and Oncology, University of Freiburg Medical Centre, Freiburg, Germany
    Br J Haematol 144:538-45. 2009
    ..This study ruled out this hypothesis by investigating the pattern of ATRX inactivation in a cross-sectional analysis of normal females at ages ranging from newborn to 90 years...
  40. ncbi request reprint Fatal outcome in a patient with metastatic prostate cancer and acquired severe hypogammaglobulinemia with complete absence of mature peripheral blood B-cells
    Jens Lohr
    Department of Hematology and Oncology, University Medical Center of Freiburg, Hugstetter Str 55, D 79106 Freiburg i Br, Germany
    In Vivo 17:505-7. 2003
    ..This case is remarkable with respect to its documented rapid evolution. Possible triggers are discussed, a combination of drug toxicities being the most likely...
  41. ncbi request reprint Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: problems and approaches
    Barbara Deschler
    Department of Hematology Oncology, University of Freiburg Hugstetterstr 55, D 79106 Freiburg, Germany
    Haematologica 91:1513-22. 2006
    ..The basis for treatment decision-making in this clinically and biologically heterogeneous group is not well defined...
  42. ncbi request reprint Autologous hematopoietic stem cell transplantation for myelodysplastic syndromes: which cell source is preferable?
    Michael Lubbert
    Department of Hematology Oncology, Albert Ludwigs University, Freiburg, Germany
    Haematologica 91:723A. 2006
  43. ncbi request reprint Decitabine in acute myeloid leukemia
    Michael Lubbert
    Department of Medicine, Division of Hematology Oncology, University of Freiburg Medical Center, Freiburg, Germany
    Semin Hematol 42:S38-42. 2005
    ..This review will provide a summary of epigenetic processes in AML and the role of the demethylating agent 5-aza-2'-deoxycytidine (decitabine; Dacogen, MGI Pharma, Inc, Bloomington, MN)...
  44. doi request reprint Immune response as a possible mechanism of long-lasting disease control in spontaneous remission of MLL/AF9-positive acute myeloid leukemia
    Claudia Müller-Schmah
    Department of Hematology and Oncology, University of Freiburg Medical Center, Hugstetter Straße 55, 79106 Freiburg, Germany
    Ann Hematol 91:27-32. 2012
    ..When the patient's natural killer (NK) cells (obtained in 2007) were tested against the K562 cell line, upregulation of CD107 occurred, implying that long-term CR in this patient could be due to NK cell-mediated disease control...
  45. ncbi request reprint Acute myeloid leukemia: epidemiology and etiology
    Barbara Deschler
    Department of Hematology Oncology, University of Freiburg, Freiburg, Germany
    Cancer 107:2099-107. 2006
    ..In contrast to these genetic alterations, epigenetic lesions, e.g., promoter silencing by hypermethylation of the p15/INK4b and other genes, are increasingly recognized as important in the pathogenesis of AML...
  46. doi request reprint Maintenance therapy in acute myeloid leukemia revisited: will new agents rekindle an old interest?
    Utz Krug
    Department of Medicine, Hematology Oncology, University of Munster, Munster, Germany
    Curr Opin Hematol 17:85-90. 2010
    ..The potential and limitations of the established cytotoxic chemotherapy for acute myeloid leukemia have been assessed by recent large-scale clinical trials. A further progress would require the contribution of alternative approaches...
  47. ncbi request reprint Imatinib mesylate as a novel treatment option for hypereosinophilic syndrome: two case reports and a comprehensive review of the literature
    Antonia M S Müller
    Hematology and Oncology Department, University Medical Center Freiburg, Hugstetterstr 55, 79106 Freiburg, Germany
    Ann Hematol 85:1-16. 2006
    ..We particularly address the issue of organ involvement and specific characteristics of the variable clinical pictures. In addition, two cases will be presented, which illustrate typical clinical scenarios and treatment outcome...
  48. doi request reprint ID2 and ID3 protein expression mirrors granulopoietic maturation and discriminates between acute leukemia subtypes
    Annette M May
    Department of Pathology, University Medical Center, Breisacher Str 115a, 79106, Freiburg, Germany
    Histochem Cell Biol 141:431-40. 2014
    ..Importantly, the distinct ID2/3 expression patterns in AL indicate a specific deregulation of ID2/3 in the various types of AL and may support subtyping of AL. ..
  49. ncbi request reprint Generalized herpes simplex virus infection in an immunocompromised patient--report of a case and review of the literature
    Georg Werner Herget
    Department of Orthopedics and Traumatology, University of Freiburg, Hugstetter Str 55, 79106 Freiburg i Br, Germany
    Pathol Res Pract 201:123-9. 2005
    ..Emphasis must be placed on clinical awareness of a generalized HSV infection in immunocompromised patients. Absence of orofacial or genital lesions does not rule out the possibility of active HSV infection...
  50. ncbi request reprint p53 Germline mutation in a patient with Li-Fraumeni Syndrome and three metachronous malignancies
    Claudia Pötzsch
    Div Hematology Oncology, University of Freiburg Medical Center, Hugstetter Str 55, 79106 Freiburg i Brsg, Germany
    J Cancer Res Clin Oncol 128:456-60. 2002
    ..Other malignancies diagnosed early in life in relatives of the mother were: prostate cancer, stomach cancer, and carcinoma of the larynx...
  51. ncbi request reprint DNA methylation disturbances as novel therapeutic target in lung cancer: preclinical and clinical results
    Werner Digel
    Department Internal Medicine, Division Hematology Oncology, University of Freiburg Medical Center, Hugstetterstr 55, D 79106 Freiburg, Germany
    Crit Rev Oncol Hematol 55:1-11. 2005
    ..Clinical trials of both groups of agents have been performed, and novel demethylating agents which are not incorporated into DNA offer further perspectives for epigenetic therapy of lung cancer and other malignancies...
  52. ncbi request reprint CXCR4 is a prognostic marker in acute myelogenous leukemia
    Anke C Spoo
    Department of Medicine, Freiburg University Hospital, Germany
    Blood 109:786-91. 2007
    ..These findings warrant further investigation into the role of CXCR4 in AML and suggest that CXCR4 should be incorporated into the risk assessment of AML patients...
  53. ncbi request reprint Williams-Beuren syndrome critical region-5/non-T-cell activation linker: a novel target gene of AML1/ETO
    Manfred Fliegauf
    Division of Hematology Oncology, University of Freiburg Medical Center, Hugstetter Str 55, D 79106 Freiburg, Germany
    Oncogene 23:9070-81. 2004
    ..The possible role of WBSCR5 in normal and malignant hematopoiesis warrants further study...
  54. ncbi request reprint Nonclonal neutrophil responses after successful treatment of myelodysplasia with low-dose 5-aza-2'-deoxycytidine (decitabine)
    Michael Lubbert
    Department of Hematology Oncology, University of Freiburg, Medical Center, Hugstetter Str 55, D 79106 Freiburg, Germany
    Leuk Res 28:1267-71. 2004
    ..In conclusion, restoration of nonclonal hematopoiesis may be the predominant effect of DAC both in early and late stages of treatment, at least in patients achieving a hematologic and cytogenetic response...